!!Tanja Fehm - Biography
\\
In 1998, Prof. Dr. Tanja Fehm began her specialist medical training at the University Women’s Hospital in Erlangen. In 1999, she started as a Postdoctoral Fellow at the Cancer Immunobiology Center in Dallas, where she established comprehensive genotyping methods for circulating tumor cells (CTCs) in breast cancer. Her scientific achievements led to her appointment in 2001 as an Adjunct Assistant Professor at her research institution. She then joined the University Women’s Hospital in Tübingen in 2002 to complete her specialist training and establish her laboratory for tumor cell dissemination. As Head of Translational Research, she initiated numerous clinical studies to evaluate the clinical significance of CTCs. Additionally, she founded the DETECT study group to assess the clinical role of CTCs in metastatic breast cancer.\\
\\
In 2010, she completed her subspecialty training in gynecologic oncology and was subsequently appointed as Senior Consultant for Gynecologic Oncology. Due to her excellent research work, she was elected as the spokesperson for the German Society for Translational Research in Gynecologic Oncology (AGO TRAFO e.V.). In 2013, she was offered the position to lead the University Women’s Hospital in Düsseldorf. In Düsseldorf, she also continued her research on CTCs and liquid biopsy and, together with Prof. Stoecklein—an expert in this field—founded the Interdisciplinary Liquid Biopsy Center to initiate joint research projects and optimize techniques for the comprehensive characterization of CTCs.\\
\\
In 2020, she was appointed as the Director of the Cancer Center Duesseldorf (CIO D). Due to her outstanding clinical expertise in gynecologic oncology, she was also elected in 2024 as the National Guidelines Officer for Gynecology and Obstetrics.\\ \\[{ALLOW view All}][{ALLOW edit tfehm}][{ALLOW upload tfehm}][{ALLOW comment All}]